Slovak Academy Opens EU Door For Russian Antiviral

BMI believes that the first significant entry of a Russian-developed pharmaceutical into the EU is on the horizon. The Slovak Academy of Sciences will reportedly certify antiviral triazavirin, developed by scientists from the Urals Branch of the Russia Academy of Sciences, for use in Europe. The move supports BMI's core view for the industry, that drugmakers based in developing countries will increase their presence in developed

To read the full article, please choose one of the following options: